Nahdi Medical Company · TADAWUL:4164
Nahdi Medical — Q3 2025 Earnings Presentation
20 slides from Nahdi Medical's earnings presentation, 2025
Slide 1: Nahdi Medical Company Investor Presentation Q3 2025
Nahdi Medical Company INVESTOR PRESENTATION Q3 2025 Nahdi Medical Company | Q3 2025 EARNINGS CALL
Slide 2: Financial Highlights
Financial Highlights Nahdi Medical Company | Q3 2025 EARNINGS CALL 3
Slide 3: 9M 2025 Financial Highlights
9M 2025 Financial Highlights (% of revenue) Q3 2025 % Change Q3 2024 Revenue 2.46B 4.6% 2.35B RESILIENT FINANCIAL Gross Profit 941M (38.2%) 11.3% 845M (35.9%) PERFORMANCE Operating Profit 188M (7.6%) 6.7% 176M (7.5%) Net Profit 161M (6.6%) 11.5% 182M (7.7%) EBITDA 390M (15.8%) 11.0% 351M (14.9%) (%
Slide 4: Solid Revenue Growth Across Businesses & Categories
Solid Revenue Growth Across Businesses & Categories Pharmacies 1,120 1,181 1,185 1,218 Revenue grew by 7.6% YoY in 9M 2025, increasing by 540.6 Clinics 6 10 9 13 million, driven by strong growth momentum across all business segments M 9,446 7.6% Retail business rose by 5.7% fueled 8,714 by continued
Slide 5: Diversified Sales Channel Growth Driving Top-Line Acceleration
Diversified Sales Channel Growth Driving Top- Line Acceleration 9,000 M +5.7% +79.4% +39.4% +7.6% 8,000 112 40 7,624 389 The Retail business continued to 7,083 lead the overall growth 7,000 6,000 Accelerated growth momentum in the Healthcare and UAE businesses. 5,000 97% 95% Contribution from Health
Slide 6: Solid Operating Profit Growth Despite Ongoing Investments
Operating Best in Class Operating Profit Margin Solid Operating Profit Growth Margin 11.0% 9.2% 9.6% 9.4% Despite Ongoing Investments The gross margin improved by 20 bps M reaching 37.4% despite the ongoing investments to support top-line growth and accelerated growth in the Healthcare and online bu
Slide 7: Attractive Net Profit Profile
Net Profit/ Attractive Net Profit Profile Net profit of 665 million, Revenue 10.2% 8.7% 9.4% 8.6% reflecting an 8.6% margin M Items below operating profit reflected a net increase in expenses of 45.4 million, primarily due to higher interest on 893 -1.2% lease liabilities, to support revenue 821 gro
Slide 8: Guidance
Guidance 9M 2025 2025 Guidance Actuals Total revenue Revenue growth 7.6% Growth (6% - 8%) Updated EPS EPS Expected to grow -1.2% annually at (1% - 2%) Capex Capex (~4%) 4.2% Expected to Dividend Policy continue at 87% (70% - 80%) in FY2024 Growth to be funded Zero Debt Capital Structure organically
Slide 9: Strategy & Operational Review
Strategy & Operational Review Nahdi Medical Company | Q3 2025 EARNINGS CALL 10
Slide 10: Our Passion for People
Our Passion for People Always Delivers Value to Our Guests 35.3 % Nationalization Invested in the success of our people No. 1 More than 500K hours of Hiring ~1000 national training conducted annually pharmacists Best Human Resource Places to Work Development Fund Always cultivating Saudi talents Str
Slide 11: Guest Satisfaction - the Cornerstone of our Strategy
Nahdi: Guest Satisfaction - the Cornerstone of our strategy Stronger Brand Equity YoY Nielsen Store Equity Index ** 69% Q2 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 of revenue generated from 6.9 7.0 7.0 6.9 6.7 Nahdi “Nuhdeek” Guests * As Q3 2025 Strong 91 NPS As Q3 2025 3.5 3.4 3.4 3.4 3.4 Moderate 1.2
Slide 12: The Retailer Suppliers Trust, Partnering for Mutual Success
Nahdi: The Retailer Suppliers Trust, Partnering for Mutual Success Rank/2 Score (100- 2 /100+) Ranked # 1 1 0 63 among 2 3 55 In Store Retailers and Pharmacies 3 0 47 Rank/1 Score (100- 4 /100+) 1 0 76 Ranked # 1 2 64 among 3 62 e-commerce Won in Q3 2025 Nahdi Medical Company | Q3 2025 EARNINGS CALL
Slide 13: Strategic Initiatives
Strategic Initiatives Nahdi Medical Company | Q3 2025 EARNINGS CALL 14
Slide 14: Introducing "Wasfaty" as a milestone in Guest care
Introducing “Wasfaty” as a milestone in Guest care As the market leader with a strong purpose, it provides us the opportunity to serve our community unique opportunity to expand our healthcare guest, reach Nahdi Medical Company | Q3 2025 EARNINGS CALL 15
Slide 15: Digital Acceleration: Seamless Experiences to Fuel Nahdi's 2025
Digital Acceleration: Seamless Experiences to Fuel Nahdi’s 2025 Record Online sales Revenue* Growth Q3 2025 Crossing 643M +23.7% vs Q3 2024 Online contribution Online sales YoY Revenue 27.7% 1,859M vs 23.0% Q3 2024 +22.3% vs 9M 2024 Nahdi Global a key 30 Min Delivery driver in Q3 2025 Quick commerce
Slide 16: Nahdi's Private Label Powerhouse; Delivering Growth & Guest Loyalty
Nahdi’s Private Label Powerhouse; Delivering Growth & Guest Loyalty YTD revenue +43.1% from 857M to 1,227M YTD Own & Differentiated Contribution 17.0% vs 12.6% 9M 2024 Robust Product Expansion: Launched 723 SKUs YTD, including 332 in Q3 alone, with a strategic focus on Beauty. Medicine Portf
Slide 17: Nahdi's Leap: Advancing National Healthcare Leadership
Nahdi’s Leap: Advancing National Healthcare Leadership Opened 3 NahdiCare Clinics in Riyadh and Abha in 9M 2025 reaching a total of 13 clinics across 9 cities in KSA Clinics business demonstrates exceptional growth, 9M 2025 Revenue +79.4% vs 9M 2024 9M 2025 Clinics business served +1,543M gues
Slide 18: Nahdi's Strategic Expansion in UAE
Nahdi's Strategic Expansion in UAE; A Robust Platform for Regional Growth Strong growth Revenue 140.5M, 39.4% and added 14 new pharmacies in 9M 2025, totaling 39 in UAE Ras Broad geographic coverage with Alkhaimah presence in all major Emirates, which Sharjah strengthens our reach Dubai UAE NP
Slide 19: 1.1 Million New Unique Guests YTD
We exist to add beats to the lives of our GUESTS 1.1 Million New Unique Guests YTD Nahdi Medical Company | Q3 2025 EARNINGS CALL 20
Slide 20: Thank You
Thank You Investor Relations Department Contacts: Website: https://investors.nahdi.sa/ Email: IR@nahdi.sa Phone: +966 556 315 822 Nahdi Medical Company | Q3 2025 EARNINGS CALL 21
Nahdi Medical Company — Q3 2025 Earnings Presentation on 6ix